Stereotaxis and Abbott Combine Technologies in First Integrated Procedures to Treat Arrhythmia Patients

July 19, 2023 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients have been successfully treated utilizing Abbott’s EnSite X EP System with Stereotaxis’ Robotic Magnetic Navigation System. 

The combination of Abbott’s leading cardiac mapping system with Stereotaxis’ advanced robotic technology brings together highly detailed real-time diagnostic information with the unprecedented precision and stability of robotics during therapy delivery. The integration of these technologies was announced at Heart Rhythm 2023. The first integrated procedures were successfully conducted by Dr. Sing-Chien Yap and Dr. Tamas Szili-Torok at Erasmus Medical Center in Rotterdam, The Netherlands, and by Dr. Burkhard Hügl at Marienhaus St. Elisabeth Hospital in Neuwied, Germany. 

“The integration of advanced mapping with the precision and safety of robotics helps provide the best therapy for patients and an enhanced workflow for physicians,” said Dr. Sing-Chien Yap. “These pioneering integrated robotic EnSite X procedures went very well, with successful treatment of patients with atrial and ventricular arrhythmias in a safe and efficient fashion.” 

“We have long championed the benefits of open interoperability in electrophysiology as a way to pair the most suitable technologies for each patient,” added Dr. Tamas Szili-Torok. “Full integrated use of EnSite X with Stereotaxis robotic technology worked smoothly and we are delighted to contribute to this progress.” 

“The community of physicians who are pioneering robotics in electrophysiology have long championed increased integrations,” said Dr. Burkhard Hügl. “The integration of both systems enables me to address the most complex arrhythmia patients. I am very pleased with this technological advance and the growing recognition that robotics plays an important role for the electrophysiology field.” 

For more information: www.stereotaxis.com 

Related Content: 

Stereotaxis and Abbott Announce Global Collaboration Combining Leading Mapping and Robotic Technologies to Improve Treatment of Abnormal Heart Rhythms 

Abbott Announces U.S. and European Approvals for New Technologies to Support Effective Treatment for Abnormal Heart Rhythms 

FDA Clears New Cardiac Mapping System to Improve How Doctors Treat Abnormal Heart Rhythms